This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Simonet WS, Lacey DL, Dunstan C et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319
Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in sk-n-mc neuronal cells. J Neurochem 86:126–135
DI Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340
Zauli G, Melloni E, Capitani S, Secchiero P (2009) Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66:841–851
Secchiero P, Corallini F, Pandolfi A et al (2006) An increased osteoprotegerin (OPG) serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236–2244
Navarra P, Dello Russo C, Mancuso C, Preziosi P, Grossman A (2000) Gaseous neuromodulators in the control of neuroendocrine stress axis. Ann NY Acad Sci 917:638–646
Wang R (2002) Two’s company, three’s a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J 16:1792–1798
Moore PK, Bhatia M, Moochhala S (2003) Hydrogen sulfide: from the smell of the past to the gas of the future? Trends Pharmacol Sci 24:609–611
Secchiero P, Candido R, Corallini F et al (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522–1530
Secchiero P, Corallini F, Gonelli A et al (2007) Anti-angiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100:61–69
Re MC, Zauli G, Gibellini D et al (1993) Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of aids patients are committed to apoptotic cell death in culture. AIDS 7:1049–1055
Zauli G, Re MC, Furlini G, Giovannini M, LA Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein GP120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73:417–421
Zauli G, Rimondi E, Stea S et al (2008) Trail inhibits osteoclastic differentiation by counteracting rankl-dependent P27KIP1 accumulation in pre-osteoclast precursors. J Cell Physiol 214:117–125
Mangan SH, Campenhout AV, Rush C, Golledge J (2007) Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 76:494–505
Zauli G, Corallini F, Bossi F et al (2007) Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110:536–543
Cross SS, Yang Z, Brown NJ et al (2006) Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118:1901–1908
Li L, Moore P (2008) Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air? Trends Pharmacol Sci 29:84–90
Szabó C (2007) Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917–993
Secchiero P, Corallini F, DI Iasio MG, Gonelli A, Barbarotto E, Zauli G (2005) Trail counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413–3419
This work was supported by a grant from FoRST—Fondazione per la Ricerca Scientifica Termale to GZ.
About this article
Cite this article
Rimondi, E., di Iasio, M.G., Gonelli, A. et al. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Invest New Drugs 30, 1731–1735 (2012). https://doi.org/10.1007/s10637-011-9675-8
- Human Umbilical Vein Endothelial Cell
- Endothelial Cell Dysfunction
- Human Umbilical Vein Endothelial Cell Culture